Jump to ContentJump to Main Navigation
Show Summary Details
More options …

LaboratoriumsMedizin

Offizielles Organ der Deutschen Vereinten Gesellschaft für Klinische Chemie und Laboratoriumsmedizin e.V. (DGKL) und affiliiert mit der Österreichischen Gesellschaft für Laboratoriumsmedizin und Klinische Chemie (ÖGLMKC)

Editor-in-Chief: Schuff-Werner, Peter

Editorial Board Member: Ahmad-Nejad, Parviz / Bidlingmaier, Martin / Borucki, Katrin / Karsten, Conrad / Fraunberger, Peter / Ghebremedhin, Beniam / Holdenrieder, Stefan / Kiehntopf, Michael / Klein, Hanns-Georg / Klouche, Mariam / Kohse, Klaus P. / Kratzsch, Jürgen / Luppa, Peter B. / März, Winfried / Nebe, Carl Thomas / Orth, Matthias / Ruf, Andreas / Sack, Ulrich / Steimer, Werner / Weber, Bernard / Wieland, Eberhard / Zettl, Uwe K.

6 Issues per year


IMPACT FACTOR 2016: 0.176
5-year IMPACT FACTOR: 0.200

CiteScore 2016: 0.27

SCImago Journal Rank (SJR) 2016: 0.140
Source Normalized Impact per Paper (SNIP) 2016: 0.101

Online
ISSN
1439-0477
See all formats and pricing
More options …
Volume 32, Issue 6 (Nov 2008)

Issues

Budd-Chiari syndrome and portal venous thrombosis – relevance of the JAK2 mutation as new risk marker1

Martin Roskos
Published Online: 2009-01-12 | DOI: https://doi.org/10.1515/JLM.2008.062et

Abstract>

A myeloproliferative disorder is the main risk factor for portal venous thrombosis or Budd-Chiari syndrome. Other significant factors are hereditary or acquired prothrombotic states and different liver diseases. Approximately 25% of thromboses occur without an indication of possible etiology. However, some patients show signs of myeloproliferative disorders on bone marrow morphology. The identification of the Janus kinase V617F mutation, which was first described in 2005, allows new insights into both the pathobiochemistry and pathophysiology of this disease, and a substantial improvement of the diagnostics at least to some of the myeloproliferative disorders. A retrospective study of clinical trials of patients with Budd-Chiari syndrome or portal venous thrombosis showed that patients with thrombosis predefined as idiopathic carried the V617F mutation at a high percentage rate and, furthermore, that a part of this patients group developed a myeloproliferative disorder after the thrombotic event.

Keywords: Budd-Chiari syndrome; Janus kinase 2; myeloproliferative disorder; portal venous thrombosis; splanchnic venous thrombosis; V617F mutation

About the article

Correspondence: Dr. med. Martin Roskos, Laborarztpraxis Roskos, Löbstedter Strasse 93, 07749 Jena, Germany Tel.: +49 (0) 3641/507420 Fax: +49 (0) 3641/507421


Published Online: 2009-01-12

Published in Print: 2008-11-01


Citation Information: LaboratoriumsMedizin, ISSN (Online) 1439-0477, ISSN (Print) 0342-3026, DOI: https://doi.org/10.1515/JLM.2008.062et.

Export Citation

Comments (0)

Please log in or register to comment.
Log in